Health TrialsbyHealthPanel

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide

The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection compared with participants with normal renal function.

Participants needed: 32
Trial details
Phase: Phase 1Age: 18-85Biological sex: AllType: InterventionalSponsor: KaileraUpdated: Sep 3, 2026Locations: 1
Eligibility criteria

Have body mass index ≥18.5 at Screening. [+3]

Have history or presence of clinically significant cardiovascular, pulmonary, he... [+8]

Read more
Status: Recruiting

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to placebo on: * Percent change in body weight * Change in hemoglobin A1c (HbA1c)

Participants needed: 1,156
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: KaileraUpdated: Sep 3, 2026Locations: 167
Eligibility criteria

Diagnosis of type 2 diabetes mellitus (T2DM). [+3]

Current diagnosis or history of type 1 diabetes mellitus (T1DM) or any other typ... [+11]

Read more
Status: Recruiting

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

Participants needed: 2,340
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: KaileraUpdated: Sep 3, 2026Locations: 104
Eligibility criteria

hypertension, [+4]

Current diagnosis or history of diabetes mellitus. [+9]

Read more
Status: Recruiting

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

Participants needed: 1,200
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: KaileraUpdated: Sep 1, 2026Locations: 59
Eligibility criteria

BMI ≥35 kilograms per square meter (kg/m²). [+1]

Current diagnosis or history of diabetes mellitus. [+9]

Read more